U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155369) titled 'UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases' on Aug. 20.
Brief Summary: This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Study Start Date: March 18
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Systemic Sclerosis
Intervention:
BIOLOGICAL: UCAR-T cells
UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.
DRUG: Cyclophosphamide
Cyclophosphamide will be administered intravenously.
DRUG: ...